Pentosan polysulfate - Paradigm Biopharma

Drug Profile

Pentosan polysulfate - Paradigm Biopharma

Alternative Names: Pentosan polysulfate sodium - Paradigm Biopharma; PPS - Paradigm Biopharma; Rhinosul; ZILOSUL

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Glycan Biosciences; Griffith University
  • Developer Griffith University; Paradigm Biopharma
  • Class Analgesics; Anti-inflammatories; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action Cell membrane permeability inhibitors; Enzyme inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ross River virus infections; Seasonal allergic rhinitis
  • Phase I/II Oedema
  • Phase I Allergic rhinitis
  • Preclinical Allergic asthma; Chikungunya virus infections
  • Research Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Jul 2017 Phase-II clinical trials in Ross River virus infections in Australia (SC) (ACTRN12617000893303)
  • 22 Jun 2017 Paradigm Biopharma plans a phase II trial for Ross River virus infections in Australia (ACTRN12617000893303)
  • 04 Apr 2017 Paradigm Biopharma plans a double-blind clinical trial in 60 patients with Bone marrow lesions associated with knee osteoarthritis in the second quarter of 2017 (Paradigm Biopharma website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top